Abbvie Inc (ABBV)

$216.26 -1.35 (-0.62%)
Market Cap 384.42B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 20.62
Forward PE 18.17
Profit Margin 7.59%
Debt to Equity Ratio -510.73
Volume 4,251,000
Avg Vol 4,903,146
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 61%
Beta 0.53
Analysts Strong Sell
Price Target $216.44

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Masonato
Masonato Sep. 17 at 2:42 PM
$ABBV https://www.investors.com/news/technology/oruka-therapeutics-biotech-stock-psoriasis-treatment/?src=A00619&refcode=aflMarketWatch&mod=mw_quote_news_topstories&_gl=1*49xvm0*_gcl_au*NTM4MzU2NTUzLjE3NTczMzgzMzE.*_ga*MzcxMzg5MzM5LjE3MTU3ODY1NDE.*_ga_K2H7B9JRSS*czE3NTgxMTU0ODgkbzE4OTYkZzEkdDE3NTgxMjAwODYkajMyJGwwJGgxNTcxMjEzNTU5
0 · Reply
TastyCheap
TastyCheap Sep. 17 at 2:09 PM
$ABBV: Mark the session’s liquidity pools; liquidity grabs often precede the real move. Not financial advice.
0 · Reply
SAS080
SAS080 Sep. 17 at 1:39 PM
$ABBV thanks 120%
0 · Reply
jbess22
jbess22 Sep. 17 at 12:07 PM
$IXHL $OPEN $ATCH $ABBV
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 17 at 11:17 AM
Enter: $ABBV OCT 10 2025 $220 CALLS Buy in Price: $3.50 - $3.68 Take Profit: $3.85 Stop Bleeding: $3.08 ROI Potential: 10% Exit Within: 21 Minutes https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 11:00 AM
Berenberg has adjusted their stance on AbbVie ( $ABBV ), setting the rating to Buy with a target price of 170 → 270.
0 · Reply
Masonato
Masonato Sep. 17 at 2:05 AM
$ABBV
0 · Reply
Masonato
Masonato Sep. 17 at 2:02 AM
$ABBV
0 · Reply
Masonato
Masonato Sep. 17 at 2:02 AM
$ABBV
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Sep. 17 at 1:49 AM
$ABBV back to 190 or what..
0 · Reply
Latest News on ABBV
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Sep 17, 2025, 7:52 AM EDT - 3 hours ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

MDT PINC

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

Sep 12, 2025, 9:57 AM EDT - 5 days ago

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

Sep 11, 2025, 12:25 PM EDT - 5 days ago

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

AbbVie in Settlement With Generic Drugmakers on Rinvoq

Sep 11, 2025, 12:17 PM EDT - 5 days ago

AbbVie in Settlement With Generic Drugmakers on Rinvoq

Why Is AbbVie Stock Trading Higher On Thursday?

Sep 11, 2025, 9:55 AM EDT - 6 days ago

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie: What's Happening With ABBV Stock?

Sep 11, 2025, 9:45 AM EDT - 6 days ago

AbbVie: What's Happening With ABBV Stock?

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Sep 10, 2025, 1:03 PM EDT - 6 days ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

AZN GSK NVO NVS SNY AMGN LLY

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 1:46 PM EDT - 7 days ago

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Sep 9, 2025, 8:00 AM EDT - 8 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 8 days ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

VEEV VRTX VST

AbbVie Declares Quarterly Dividend

Sep 5, 2025, 9:07 AM EDT - 12 days ago

AbbVie Declares Quarterly Dividend

Global drugmakers rush to boost US presence as tariff threat looms

Sep 3, 2025, 2:09 PM EDT - 13 days ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD JNJ LLY MRK

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sep 3, 2025, 8:30 AM EDT - 14 days ago

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 15 days ago

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

How To Invest $100,000 In A Near-Perfect Strategy Portfolio

Aug 30, 2025, 8:05 AM EDT - 18 days ago

How To Invest $100,000 In A Near-Perfect Strategy Portfolio

ADX BME CVX EOS FDVV HD JEPQ

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

Aug 29, 2025, 12:37 PM EDT - 18 days ago

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.

Aug 28, 2025, 2:41 PM EDT - 19 days ago

Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.

JNJ LLY XLV

Best Dividend Aristocrats For September 2025

Aug 27, 2025, 2:09 PM EDT - 20 days ago

Best Dividend Aristocrats For September 2025

ABT ADM ADP AFL ALB AMCR AOS

AbbVie: Plenty Of Positives

Aug 26, 2025, 1:24 PM EDT - 21 days ago

AbbVie: Plenty Of Positives

AbbVie Is A Top Biotech Pick

Aug 25, 2025, 9:18 AM EDT - 23 days ago

AbbVie Is A Top Biotech Pick

AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion

Aug 25, 2025, 9:09 AM EDT - 23 days ago

AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Aug 25, 2025, 8:59 AM EDT - 23 days ago

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Best Dividend Kings: August 2025

Aug 24, 2025, 10:13 PM EDT - 23 days ago

Best Dividend Kings: August 2025

ABM ABT ADM AWR BDX BKH CINF

AbbVie Investors Beware: Strong Growth Potential, Rising Risks

Aug 23, 2025, 10:31 AM EDT - 25 days ago

AbbVie Investors Beware: Strong Growth Potential, Rising Risks

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

Aug 21, 2025, 8:30 AM EDT - 27 days ago

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

AbbVie Completes Acquisition of Capstan Therapeutics

Aug 19, 2025, 8:55 AM EDT - 4 weeks ago

AbbVie Completes Acquisition of Capstan Therapeutics

SkinMedica® Unveils Its Newest Hydration Hero

Aug 19, 2025, 8:00 AM EDT - 4 weeks ago

SkinMedica® Unveils Its Newest Hydration Hero

My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys

Aug 13, 2025, 8:15 AM EDT - 5 weeks ago

My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys

AAPL AGNC AM APLE ARCC ARI AVGO

AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition

Aug 12, 2025, 4:59 PM EDT - 5 weeks ago

AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

Aug 12, 2025, 1:00 PM EDT - 5 weeks ago

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Aug 8, 2025, 1:23 PM EDT - 5 weeks ago

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

GMAB

Get Ready, JUVÉDERM® Day is Calling!

Aug 6, 2025, 8:00 AM EDT - 6 weeks ago

Get Ready, JUVÉDERM® Day is Calling!

Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency

Aug 5, 2025, 8:00 AM EDT - 6 weeks ago

Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency

The Big 3: ABBV, ETSY, VRT

Aug 4, 2025, 12:34 PM EDT - 6 weeks ago

The Big 3: ABBV, ETSY, VRT

ETSY VRT

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

Aug 1, 2025, 2:04 PM EDT - 6 weeks ago

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

5 Dividend Stocks With Solid Returns And More Growth Ahead

Aug 1, 2025, 12:33 PM EDT - 6 weeks ago

5 Dividend Stocks With Solid Returns And More Growth Ahead

AVGO CI CVS NRG

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Aug 1, 2025, 12:01 PM EDT - 6 weeks ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

AMGN AZN BMY GILD GSK JNJ LLY

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 6 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABT ALNY AMGN ARGX AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 6 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABT ALNY AMGN ARGX AZN BAX BIIB

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

Jul 31, 2025, 3:35 PM EDT - 6 weeks ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

AMGN AZN BMY GILD GSK JNJ LLY

AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 3:13 PM EDT - 6 weeks ago

AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

Jul 31, 2025, 3:00 PM EDT - 6 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

AMGN AZN BMY GILD GSK JNJ LLY

Trump pressures 17 pharma CEOs to cut US drug prices

Jul 31, 2025, 2:28 PM EDT - 6 weeks ago

Trump pressures 17 pharma CEOs to cut US drug prices

AMGN AZN BMY GILD GSK JNJ LLY

Trump posts letters to 17 pharmaceutical companies about drug prices

Jul 31, 2025, 2:19 PM EDT - 6 weeks ago

Trump posts letters to 17 pharmaceutical companies about drug prices

GILD LLY PFE AMGN AZN BMY GSK

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Jul 31, 2025, 1:48 PM EDT - 6 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

AMGN AZN BMY GILD GSK JNJ LLY

AbbVie Stock Pops After Earnings Beat and Guidance Raised

Jul 31, 2025, 8:08 AM EDT - 6 weeks ago

AbbVie Stock Pops After Earnings Beat and Guidance Raised

AbbVie lifts annual profit forecast on strong demand for newer immunology drugs

Jul 31, 2025, 7:51 AM EDT - 6 weeks ago

AbbVie lifts annual profit forecast on strong demand for newer immunology drugs

AbbVie Reports Second-Quarter 2025 Financial Results

Jul 31, 2025, 7:44 AM EDT - 6 weeks ago

AbbVie Reports Second-Quarter 2025 Financial Results

AbbVie in talks to acquire Gilgamesh Pharmaceuticals

Jul 30, 2025, 6:28 PM EDT - 6 weeks ago

AbbVie in talks to acquire Gilgamesh Pharmaceuticals

Sell AbbVie Stock Ahead of Its Upcoming Earnings?

Jul 30, 2025, 9:30 AM EDT - 7 weeks ago

Sell AbbVie Stock Ahead of Its Upcoming Earnings?

Masonato
Masonato Sep. 17 at 2:42 PM
$ABBV https://www.investors.com/news/technology/oruka-therapeutics-biotech-stock-psoriasis-treatment/?src=A00619&refcode=aflMarketWatch&mod=mw_quote_news_topstories&_gl=1*49xvm0*_gcl_au*NTM4MzU2NTUzLjE3NTczMzgzMzE.*_ga*MzcxMzg5MzM5LjE3MTU3ODY1NDE.*_ga_K2H7B9JRSS*czE3NTgxMTU0ODgkbzE4OTYkZzEkdDE3NTgxMjAwODYkajMyJGwwJGgxNTcxMjEzNTU5
0 · Reply
TastyCheap
TastyCheap Sep. 17 at 2:09 PM
$ABBV: Mark the session’s liquidity pools; liquidity grabs often precede the real move. Not financial advice.
0 · Reply
SAS080
SAS080 Sep. 17 at 1:39 PM
$ABBV thanks 120%
0 · Reply
jbess22
jbess22 Sep. 17 at 12:07 PM
$IXHL $OPEN $ATCH $ABBV
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 17 at 11:17 AM
Enter: $ABBV OCT 10 2025 $220 CALLS Buy in Price: $3.50 - $3.68 Take Profit: $3.85 Stop Bleeding: $3.08 ROI Potential: 10% Exit Within: 21 Minutes https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 11:00 AM
Berenberg has adjusted their stance on AbbVie ( $ABBV ), setting the rating to Buy with a target price of 170 → 270.
0 · Reply
Masonato
Masonato Sep. 17 at 2:05 AM
$ABBV
0 · Reply
Masonato
Masonato Sep. 17 at 2:02 AM
$ABBV
0 · Reply
Masonato
Masonato Sep. 17 at 2:02 AM
$ABBV
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Sep. 17 at 1:49 AM
$ABBV back to 190 or what..
0 · Reply
Masonato
Masonato Sep. 16 at 9:16 PM
$ABBV Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227 https://finviz.com/news/167786/guggenheim-reiterates-a-buy-rating-on-abbvie-abbv-sets-a-pt-of-227
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 5:15 PM
$ABBV up 23% YTD — time to buy, hold, or sell? 📈 Skyrizi and Rinvoq are powering growth, more than offsetting Humira declines and setting up long-term momentum. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2752221/is-abbv-stock-a-buy-hold-or-sell-after-its-almost-23-rise-ytd?cid=sm-stocktwits-2-2752221-teaser-12706&ADID=SYND_STOCKTWITS_TWEET_2_2752221_TEASER_12706
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Sep. 16 at 4:39 PM
$SLS was a $70M Mcap when the IDMC Unblinded Actual Phase 3 MOS and IR Data from the Interim Analysis - which tells everyone, Gps is Golden. $ABBV and $BMY who Aza + VEN, BAT for Control Arm Patients - Know PRECISELY how their Drugs Perform - and SLS's Market value is UP Nearly 200%... Says Much. Similarly, the Number of Institutional Investors has nearly Quadrupled from 39 2 quarters ago to 124 FUNDS invested here -- AND NOT 1 FUND is Only Short. All the short ID's working here begging for Sellers - are Sc_mBAG Liars.
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 4:15 PM
$ABBV up 22.5% YTD — is the rally just getting started? 🚀 🎯 Skyrizi & Rinvoq sales replacing Humira's decline 💊 Oncology & neuroscience segments driving growth 🛒 More than 30 M&A transactions since the beginning of 2024 bolstering pipeline Stay invested or take profits? Full analysis here 👉 https://www.zacks.com/stock/news/2752221/is-abbv-stock-a-buy-hold-or-sell-after-its-almost-23-rise-ytd?cid=sm-stocktwits-2-2752221-body-12690&ADID=SYND_STOCKTWITS_TWEET_2_2752221_BODY_12690
0 · Reply
Masonato
Masonato Sep. 16 at 4:01 PM
$ABBV https://finviz.com/news/167493/is-abbv-stock-a-buy-hold-or-sell-after-its-almost-23-rise-ytd
0 · Reply
Masonato
Masonato Sep. 16 at 4:01 PM
$ABBV https://finviz.com/news/167227/abbvie-abbvs-dividend-track-record-how-it-became-a-leader-in-consistent-dividends
0 · Reply
Jblack500
Jblack500 Sep. 16 at 12:42 PM
$GILD $ABBV $BBIO gilead jp morgan pt 135 to 145. Time to buy the "rfk junior unqualified to make healthcare policy dip". Bbio getting closer to pivotal data release.
0 · Reply
JarvisFlow
JarvisFlow Sep. 16 at 12:00 PM
JP Morgan has adjusted their stance on AbbVie ( $ABBV ), setting the rating to Overweight with a target price of 200 → 235.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Sep. 16 at 12:36 AM
$SLS It is a Fact: +/- 60 Events From the Control ARM and we still have yet to See 80. - can any of the many Paid Short Lowlife ID's at work here, find 1 trial - JUST 1, where AML CR2 patients NOT Getting Transplant - are Surviving beyond 12 months? a little help for you... AZA VEN Trials BAT for Control --- and remember, the VIALE-M Phase 3 AML Trial for CR1 Patients JUST FAILED... $ABBV Discontinued it because the Toxicity was preventing Enrollment... Had to be Real Bad to Close a P3 .. . . 94% Grade 3 or 4 Side Effects...
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Sep. 15 at 8:10 PM
$SLS $ABBV VIALE-M - Aza Ven AML FIRST REMISSION PHASE 3 TRIAL FAIL. M for maintenance - Failed Aza Ven is BAT FOR THE SLS P3 CONTROL ARM
1 · Reply
SAS080
SAS080 Sep. 15 at 7:36 PM
$ABBV 215C 70% from lows..
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Sep. 15 at 6:28 PM
$SLS The SLS Phase 3 REGAL TRIAL IDMC Unblinded Actual Phase 3 Trial Data: -- ALL POOLED P3 Patients have A MOS that is/was Not Yet Met and > Greater than 13.5 months @Dogtag to clarify -- its not ME - saying BAT is a FAIL, its $ABBV saying it... - the VIALE-M Fail is another Ven Aza Fail in addition to the VERONA P3 fail a couple weeks ago... Gps Phase 3 Control patients on BAT have dismal Outcomes, according to 3 Dr's - Dr's who treat 15% of the Actual Enrolled P3 trial patients. Dr Levy the dir. of Hematological research at Baylor, Median Overall Survival for patients on BAT is not Durable - just 6-8 months. Dr Jamy MOS is only 6-8 months Dr. Tsirigotis Mos is extremely poor for patients on Aza Ven on the order of 5-7 months....
0 · Reply